Key takeaways
Trulicity (dulaglutide) and Mounjaro (tirzepatide) are both once-weekly injectable medications used to manage Type 2 diabetes. However there are some important differences. Trulicity is a GLP-1 receptor agonist, while Mounjaro is both a GLP-1 and GIP receptor agonist. Trulicity is approved for people 10 years and older, while Mounjaro is only approved for adults. Trulicity also has an additional FDA-approved indication to lower the risk of heart problems in adults with Type 2 diabetes who have heart disease or risk factors. The starting dose for Trulicity is 0.75 mg, with a maximum of 4.5 mg weekly for adults, whereas Mounjaro starts at 2.5 mg and can go up to 15 mg weekly. Both are only available as branded medications. Common side effects for both include nausea, vomiting, and diarrhea and an increased risk of thyroid cancer and pancreatitis. They should not be used by people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
